best peptides FAQ

Discard it. Any temperature excursion above 8°C for more than 2 hours causes protein denaturation. The peptide may appear unchanged but the amino-acid structure has degraded into inactive fragments. Using degraded peptides wastes money and delays healing because you're injecting non-functional compounds. Proper cold-chain management isn't optional.

Consider peptide therapy when you've completed at least three months of cyclosporine or lifitegrast without meaningful symptom reduction (defined as less than 30% improvement in OSDI score or Schirmer test results). The failure isn't your biology. It's mechanism mismatch. Immune modulators work for T-cell-mediated inflammation but do nothing for aqueous deficiency from lacrimal gland atrophy or lipid deficiency from meibomian gland dropout. Thymosin Beta-4 directly stimulates lacrimal secretion through aquaporin channels, bypassing the immune pathway entirely. Patients in the ReGenTree trials who'd previously failed cyclosporine showed the same response magnitude as treatment-naive patients, meaning prior therapy failure doesn't predict peptide response.

TB-500 is the better choice for acute inflammatory flare-ups because it reduces pro-inflammatory cytokines while simultaneously supporting tissue repair. Research from the National Heart, Lung, and Blood Institute found that TB-500 administration reduced IL-6 and TNF-alpha levels. The same signaling molecules that spike after high-volume training and cause swelling, stiffness, and reduced range of motion. Unlike NSAIDs, which block inflammation indiscriminately, TB-500 allows the repair process to continue while dampening the excessive inflammatory response.

Yes. Creatine restores phosphocreatine for ATP regeneration (an energy substrate issue), while peptides repair tissue damage at the structural level. They address entirely different limiting factors. A swimmer with full creatine saturation can still experience delayed recovery if muscle fibers aren't rebuilding fast enough between sessions. TB-500 accelerates actin repolymerization in damaged myocytes, a process creatine doesn't influence. Beta-alanine buffers intracellular hydrogen ions to delay fatigue onset, but it doesn't enhance post-session collagen synthesis or angiogenesis. Both critical for tendon and ligament recovery. The mechanisms don't overlap; they stack.

No, but you've missed the acute inflammation and early angiogenesis windows where BPC-157 delivers maximum impact. TB-500 and GHK-Cu remain highly effective during weeks 2–8 because cellular migration and collagen remodelling are still active processes. Focus your protocol on TB-500 (2–5 mg twice weekly) and GHK-Cu (1–2 mg daily) rather than adding BPC-157 retroactively. The remodelling phase lasts months. Peptides deployed even 4–6 weeks post-op can still improve final tissue quality and reduce scar visibility, though swelling reduction benefits are minimal at that stage.

Administer BPC-157 at 250–500 mcg daily, preferably via subcutaneous injection near the affected elbow. The mechanism works through localized VEGF upregulation, so proximity to the injury site improves angiogenesis in the damaged tendon. Research shows effects begin within 7–10 days but peak tissue remodeling occurs across 4–6 weeks of consistent administration.

This signals immune dysregulation. Specifically Treg depletion and mucosal IgA suppression. Thymalin is the targeted intervention: administer 5 mg intramuscularly every other day for 10 doses (20-day protocol). Food sensitivities post-antibiotics aren't true allergies. They're a consequence of increased intestinal permeability allowing food proteins to cross the barrier intact, triggering IgG-mediated immune reactions. Thymalin restores the Treg population that prevents these overreactions. Simultaneously eliminate the top trigger foods (dairy, gluten, eggs, soy) for 30 days while the immune system recalibrates.

Reassess three variables: peptide dosing accuracy, reconstitution protocol, and injury severity. Underdosing is common. 100 mcg BPC-157 daily may be subtherapeutic for a complete tendon tear, while 400 mcg shows measurable effects in literature. Reconstitution errors (using sterile water instead of bacteriostatic water, incorrect vial mixing ratios) denature peptides and render them inactive. If dosing and handling are correct, the injury may involve structural damage requiring surgical intervention. Peptides accelerate biological healing, but they can't replace torn tissue that lacks mechanical continuity.

Verify peptide purity through third-party testing (HPLC or mass spectrometry). Counterfeit or degraded peptides are common in unregulated markets, and visual inspection cannot detect potency loss. If purity is confirmed, reassess injection technique: are you administering the peptide within 1–2 cm of the injury site, or injecting into abdominal subcutaneous fat where systemic distribution dilutes local concentration? Switch to peritendinous injection (subcutaneous tissue directly overlying the injured tendon) rather than remote sites. If no improvement occurs after six weeks of properly administered high-purity peptide, the injury may involve structural damage (partial tendon tear, bone spur impingement) that requires mechanical intervention (corticosteroid injection, platelet-rich plasma, or surgical debridement) rather than biochemical signaling alone.

Combine BPC-157 for localized soft tissue repair with cerebrolysin or dihexa for neuroprotection. These peptides target different pathways and don't interfere with each other. BPC-157 administered subcutaneously near the injury site addresses ligament and tendon damage, while cerebrolysin supports synaptic repair and reduces neuroinflammation systemically. Clinical protocols often layer these interventions, starting cerebrolysin within 72 hours of the accident (when neuroprotection is most critical) and continuing BPC-157 for 4–6 weeks as soft tissue heals.

Discard it immediately. Cloudiness indicates protein aggregation from improper pH, bacterial contamination, or temperature shock during reconstitution. Aggregated peptides lose bioactivity and can trigger immune responses. Ensure bacteriostatic water is at room temperature before mixing, inject it slowly down the vial wall rather than directly onto the lyophilized powder, and swirl gently. Never shake. Store reconstituted peptides at 2–8°C and use within 28 days for BPC-157 and TB-500, 14 days for GHK-Cu due to copper oxidation.

GHK-Cu at 1.5 mg daily provides baseline anti-inflammatory coverage without the acute injury focus of BPC-157 or TB-500. Some competitive players add low-dose TB-500 (2 mg weekly) during high-volume blocks to preemptively support tissue remodeling before overuse symptoms appear. Preventative protocols work best when combined with structured recovery: contrast therapy post-round, dynamic stretching pre-round, and load management (reducing practice volume during tournament weeks). Peptides aren't a substitute for biomechanical efficiency. A swing generating excessive shoulder torque will eventually overwhelm any recovery protocol.

Stop playing immediately. Continued loading under acute inflammation compounds microtrauma into macroscopic tissue damage. Ice for 15 minutes within the first hour, then begin BPC-157 within 6 hours post-injury at 300 mcg twice daily. Add TB-500 at 3 mg twice weekly if pain doesn't resolve within 72 hours, indicating muscle involvement beyond isolated tendon strain. Most acute rotator cuff strains (Grade I or II) respond within 2–3 weeks; if pain worsens or night pain develops, imaging (MRI) is warranted to rule out partial-thickness tears requiring different intervention.

Administer immediately but adjust expectations. Therapeutic benefit drops to approximately 30% of pre-loaded protocols. The physiological reason: hypoxia triggers HIF-1α within 6–12 hours, initiating inflammatory cascades before peptide plasma levels reach therapeutic range. For Thymalin specifically, starting post-ascent misses the thymic precursor window entirely. You're attempting to restore T-cells that hypoxia already suppressed. Best salvage protocol: double the standard daily Cerebrolysin dose (10mL IV) for the first three administrations to achieve rapid blood-brain barrier stabilization, then taper to 5mL maintenance.

No peptide regenerates human cochlear hair cells. Mammals lack the regenerative capacity present in birds and some fish. What peptides like BPC-157 or Cerebrolysin may offer is slowing further degeneration by improving cochlear blood flow or supporting surviving neurons. In our experience reviewing clinical use cases, patients with early presbycusis (mild high-frequency loss) report subjective stabilization more often than those with severe multiyear decline. The biological window for intervention narrows as damage accumulates.

Administer TB-500 and GHK-Cu instead of BPC-157. The angiogenic window for BPC-157 closes after initial hematoma resolution. Capillary formation peaks in days 3–10 post-fracture, and VEGF upregulation after that point yields diminishing returns. TB-500 retains value through the soft callus phase (weeks 2–4) because stem cell recruitment continues throughout that period, and GHK-Cu supports mineralization during hard callus development (weeks 4–8). Starting late means skipping the angiogenic phase, but the subsequent phases still respond to targeted peptide intervention.

Most peptides used in recovery research aren't FDA-approved drugs for human use. They're research compounds studied extensively in preclinical and veterinary models but not yet through Phase 3 human trials for specific indications. This doesn't mean they're unsafe or ineffective; it means regulatory approval lags research evidence by 10–15 years in many cases. Providers familiar with regenerative medicine or sports injury research are more likely to understand the mechanisms and applications. Resources from Real Peptides include published research summaries and third-party purity testing documentation that can inform clinical discussions.

Discard it immediately. Cloudiness indicates protein aggregation or bacterial contamination, both of which render the solution unsafe and ineffective. Properly reconstituted BPC-157 and TB-500 should be completely clear with no visible particles. If cloudiness appears after refrigerated storage, the peptide has degraded due to temperature fluctuation or exceeded its 30-day stability window. This isn't salvageable. Using degraded peptides introduces particulate matter subcutaneously with zero therapeutic benefit and potential infection risk.

Descend immediately. Peptides reduce HACE risk but don't eliminate it. Severe headache unresponsive to rest and hydration within 4–6 hours signals potential cerebral edema formation that's progressing faster than Cerebrolysin can stabilize. The peptide delays onset and reduces severity, but individual variation in blood-brain barrier vulnerability means some subjects develop HACE despite optimal protocols. Monitor for ataxia (inability to walk heel-to-toe in straight line) or altered mental status. Either symptom mandates descent regardless of peptide regimen.

Mild redness lasting 10–15 minutes post-injection is normal and indicates localized immune response to the injection itself, not the peptide. Persistent swelling, heat, or pain lasting more than 2 hours suggests either technique error (injecting too quickly, using a dull needle) or contamination. Switch to a fresh vial, ensure proper alcohol prep of the injection site, and inject more slowly. If reactions continue with a new vial, discontinue use. You may have developed a sensitivity to the bacteriostatic water preservative (benzyl alcohol) rather than the peptide itself.